OrthoPediatrics Projects Strong 2026 Growth, Adjusted EBITDA Doubling, and Free Cash Flow Breakeven

summarizeSummary

OrthoPediatrics Corp. filed an investor presentation detailing its full year 2025 financial results and providing strong 2026 guidance, including projected revenue growth, a near-doubling of Adjusted EBITDA, and Free Cash Flow breakeven.

check_boxKey Events

• Reports Full Year 2025 Financial Results

  The company reported $236.3 million in total revenue for full year 2025, representing 15% growth over 2024, with a net loss of ($39.6 million) and diluted EPS of ($1.69).

• Issues Strong 2026 Financial Guidance

  OrthoPediatrics projects 2026 revenue between $262.0 million and $266.0 million (11% to 13% growth), Adjusted EBITDA of approximately $25.0 million (nearly double 2025's $14.8 million), and anticipates achieving Free Cash Flow breakeven.

• Highlights Strategic Growth Initiatives

  The investor presentation details ongoing aggressive R&D, strategic acquisitions like Boston Orthotics & Prosthetics, and expansion of its Specialty Bracing (OPSB) division with plans for 18 new markets by 2027.

• Provides Comprehensive Business Overview

  The filing includes a detailed investor presentation outlining the company's market opportunity, broad product portfolio, commercial execution, and commitment to clinical education in pediatric orthopedics.

auto_awesomeAnalysis

This 8-K filing, accompanied by a comprehensive investor presentation, provides a detailed update on OrthoPediatrics' strategic direction and financial outlook. The most significant takeaway is the robust 2026 guidance, which projects substantial growth in Adjusted EBITDA and a move towards Free Cash Flow breakeven. This signals a positive shift towards profitability and improved financial health for the growth-oriented company. The detailed presentation also reinforces the company's strong market position in pediatric orthopedics, aggressive R&D, and strategic expansion plans, which are crucial for long-term value creation.